Argos Therapeutics (NASDAQ: ARGS) and 3SBio (NASDAQ:SSRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Argos Therapeutics and 3SBio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 3 0 0 2.00
3SBio 0 0 1 0 3.00

Argos Therapeutics presently has a consensus target price of $4.13, suggesting a potential upside of 2,331.37%. Given Argos Therapeutics’ higher possible upside, equities analysts clearly believe Argos Therapeutics is more favorable than 3SBio.

Valuation and Earnings

This table compares Argos Therapeutics and 3SBio’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Argos Therapeutics $950,000.00 9.84 -$53.02 million ($1.48) -0.11
3SBio N/A N/A N/A $0.73 22.73

3SBio has higher revenue, but lower earnings than Argos Therapeutics. Argos Therapeutics is trading at a lower price-to-earnings ratio than 3SBio, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

27.9% of Argos Therapeutics shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Argos Therapeutics and 3SBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -12,391.15% -1,532.49% -92.03%
3SBio N/A N/A N/A

Volatility & Risk

Argos Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, 3SBio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

3SBio beats Argos Therapeutics on 7 of the 11 factors compared between the two stocks.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

3SBio Company Profile

3SBio Inc. is a biotechnology company in the People’s Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.